Cost-effectiveness analysis in the context of "Essential medicines"

Play Trivia Questions online!

or

Skip to study material about Cost-effectiveness analysis in the context of "Essential medicines"

Ad spacer

⭐ Core Definition: Cost-effectiveness analysis

Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the relative costs and outcomes (effects) of different courses of action. Cost-effectiveness analysis is distinct from cost–benefit analysis, which assigns a monetary value to the measure of effect. Cost-effectiveness analysis is often used in the field of health services, where it may be inappropriate to monetize health effect. Typically the CEA is expressed in terms of a ratio where the denominator is a gain in health from a measure (years of life, premature births averted, sight-years gained) and the numerator is the cost associated with the health gain. The most commonly used outcome measure is quality-adjusted life years (QALY).

Cost–utility analysis is similar to cost-effectiveness analysis. Cost-effectiveness analyses are often visualized on a plane consisting of four quadrants, the cost represented on one axis and the effectiveness on the other axis. Cost-effectiveness analysis focuses on maximising the average level of an outcome, distributional cost-effectiveness analysis extends the core methods of CEA to incorporate concerns for the distribution of outcomes as well as their average level and make trade-offs between equity and efficiency, these more sophisticated methods are of particular interest when analysing interventions to tackle health inequality.

↓ Menu

>>>PUT SHARE BUTTONS HERE<<<

👉 Cost-effectiveness analysis in the context of Essential medicines

Essential medicines, as defined by the World Health Organization (WHO), are medicines that "satisfy the priority health care needs of the population". Essential medicines should be accessible to people at all times, in sufficient amounts, and be generally affordable. Since 1977, the WHO has published a model list of essential medicines, with the 2023 list for adult patients containing over 500 medicines. Since 2007, a separate list of medicines intended for child patients has been published. A new list was published in 2021, for both adults and children.

Several changes have been implemented since the 2021 edition, including that medication cost should not be grounds for exclusion criteria if it meets other selection criteria, and cost-effectiveness differences should be evaluated within therapeutic areas. The following year, antiretroviral agents, usually used in the treatment of HIV/AIDS, were included on the list of essential medicines.

↓ Explore More Topics
In this Dossier